Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions  by Ibrahim, Mohammed F.K. et al.





E-mjournal homepage: www.elsevier.com/locate/jboResearch PaperStrategies for obtaining bone biopsy specimens from breast cancer
patients – Past experience and future directions
Mohammed F.K. Ibrahim a, John Hilton a,b, Christina Addison b, Susan Robertson c,
Joel Werier d, Sasha Mazzarello b, Lisa Vandermeer b, Carmel Jacobs a, Mark Clemons a,b,n
a Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada
b Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada
c Division of Anatomical Pathology, Eastern Ontario Regional Laboratory Association, Ottawa, Ontario, Canada
d Division of Orthopaedic Surgery, The Ottawa Hospital, Ottawa, Ontario, Canadaa r t i c l e i n f o
Article history:
Received 18 April 2016
Received in revised form
4 July 2016
Accepted 5 July 2016





74/& 2016 The Authors. Published by Elsevier
reativecommons.org/licenses/by-nc-nd/4.0/).
esponding author at: Division of Medical On
Centre, 501 Smyth Road, Ottawa, Canada.
ail address: mclemons@toh.ca (M. Clemons).a b s t r a c t
Background: Cancer and its treatment can have multiple effects on the bone. Despite the widespread use
of in vivo and in vitro models, it is still necessary to understand these effects in humans. Obtaining
human bone biopsies is technically challenging and in this article we review the experiences from the
Ottawa Bone Oncology Program.
Methods: A series of bone biopsy studies in breast cancer patients with and without bone metastasis
have been performed. We reviewed the results of these studies and present them in a descriptive
manner. We discuss lessons learned from each project and how they have affected future directions for
research.
Results: Since 2009, 5 studies have been performed accruing 97 breast cancer patients. Study endpoints
have ranged from comparing the yield of malignant cells from CT-guided versus standard iliac crest
biopsies, to studies assessing the feasibility of micro-CT analysis on Jedhadi trephines to evaluate bi-
sphosphonate effects on bone micro-architecture. More recently, we have assessed the feasibility of
performing repeat bone biopsies in the same patient as well as evaluating the practicality of obtaining
bone tissue at the time of orthopaedic surgery.
Conclusion: Human bone tissue is an important biological resource. Our experience suggests that ob-
taining bone biopsies is feasible and can yield adequate amount of tumour cells for many studies.
However, these remain technically challenging specimens to obtain and given the rapid advances in
cancer therapeutics and the use of potent adjuvant bone-targeted agents, more centres need to be in-
volved in these types of studies.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the last few decades bone oncology research has tended
to focus on the mechanisms of bone destruction when tumour
cells are present [1–3]. The realisation of the important interplay
between the tumour cell, the bone microenvironment and the
osteoclast in particular led to the rapid expansion of clinical stu-
dies with bone-targeting agents, such as bisphosphonates and
denosumab [4,5]. However, with the advent of more effective anti-
cancer therapies, as well as studies demonstrating alterations in
estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (Her2) status between primaryGmbH. This is an open access art
cology, The Ottawa Hospitaland metastatic sites, there has been increasing interest in evalu-
ating the actual biological effects of cancer and its treatment on
the bone in patients themselves [6,7]. Indeed, the expanding role
of adjuvant bisphosphonates would suggest that more in vivo
studies in patients are actually needed [8,9].
Despite the growing knowledge about the bone micro-
environment, it is clinically evident that the information so far
derived from the use of animal models and cell lines has not been
consistently predictive of beneﬁt in patients [10–12]. For example,
despite models suggesting signiﬁcant direct and indirect anti-tu-
mour effects of bone-targeted agents, to date their effects on bone
response rates, progression free or overall survival in patients with
metastatic disease has been modest [13–15]. In addition, the issue
around the adjuvant use of bisphosphonates has become clinically
challenging; initial animal models suggested bisphosphonates
were most effective in a high bone turnover environment, how-
ever a recent meta-analysis would suggest that the clinical beneﬁticle under the CC BY-NC-ND license
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quently animal models that mimic a low estrogen/postmenopausal
environment have been developed and recent data suggest that
the combination of bisphosphonate and a low estrogen environ-
ment can inhibit tumour growth, an effect that is not seen in the
premenopausal/high estrogen environment. This ﬁnding gives a
biological rationale for the clinical results seen with adjuvant bi-
sphosphonates in the postmenopausal patient [12].
Given the limitation of current in vitro and in vivo animal
models, human bone biopsy tissue represents a valuable resource
for further research efforts and for guiding clinical care [15]. Un-
fortunately, bone remains one of the more technically difﬁcult
areas to biopsy. In this paper we will discuss a series of studies that
have been performed by the Ottawa Bone Oncology Program
(OBOP) outlining the types of studies we have performed and the
challenges of performing such studies. We will evaluate future
directions where we feel studies of human bone metastasis tissue
could potentially yield the most beneﬁts to patients.2. Methods
Since 2009, a series of studies were conducted at The Ottawa
Hospital Cancer Centre. Each study received local Research Ethics
Board approval and evaluated a range of different endpoints. We
have reviewed the results of these studies and present them in a
descriptive manner. We also discuss some of the challenges faced
by each project and how we have tried to incorporate these les-
sons into subsequent projects (Table 1).
2.1. Is the yield of metastatic tumour cells similar with CT-guidance
and standard iliac crest trephine biopsy?
With signiﬁcant hormone status discordance between primary
and metastatic sites in breast cancer patients having been reported
[16–18], acquisition of metastatic tissue may have important im-
plications in planning subsequent treatments. Amir et al. reported
that biopsy of any site of metastatic recurrence at the time of ﬁrst
metastases led to change in management of 14% of women with
breast cancer (95% CI, 8.4% to 21.5%) [19], as a result of change in
the expression of ER, PR and Her2 receptors [19]. While tissue
acquisition for visceral and nodal sites can be relatively straight
forward, acquisition of metastatic tissue from patients with bone-
only sites of recurrence can lead to additional challenges. In this
situation, there are two acceptable methods of bone tissue ac-
quisition: bone marrow aspiration and biopsy from the iliac crest;
or CT-guided bone biopsy. Bone marrow trephine/aspiration is
traditionally performed in the outpatient clinic using Jamshidi
bone biopsy needles. While CT-guided biopsies are performed in
the radiology suite by an interventional radiologist, who willTable 1
Lessons learned from the creation of the Ottawa Bone Oncology Program.
Study types Lessons learned:
Issues affecting all studies  Ensure consent covers future
 Biopsies should be performed
 Standard operating procedure
 The yield of tumour cells is re
Studies exploring bone quality  Jamshidi biopsy needle can be
Studies evaluating repeat biopsies  Patients are often willing to u
 Low tumour yields a signiﬁcan
 The number of specimens wit
patient will be relatively low.
Studies obtaining specimens from surgical
specimens
 Coordination between multipl
 Advanced notiﬁcation is desir
 The abundance of tumour avachoose the safest skeletal site to biopsy. There are important cost
and logistical issues associated with each of these techniques with
CT-guided biopsies being signiﬁcantly more expensive. Once tissue
is obtained, samples can be analysed by microscopy, im-
munohistochemistry [20]and if sufﬁcient tumour cells are ob-
tained, gene expression proﬁling can be conducted [9]. Success of
such analysis depends on the quality and source of the specimen
but in one study we showed that the analysable yield of sufﬁcient
RNA for microarray analysis was 60% from bone metastasis core
needle biopsies and 80% from bone marrow aspirate specimens
[9].
In a single arm feasibility study to compare the two types of
biopsy, Hilton et al. assessed whether bone marrow trephine/as-
piration biopsy can be utilised in place of CT-guided biopsy of bone
metastases in patients with metastatic breast cancer [20]. Patients
underwent a CT-guided bone biopsy followed by a standard out-
patient bone marrow aspirate and trephine performed from the
posterior iliac crest. Forty patients entered the study and tumour
cells were identiﬁed at similar rates from both the iliac crest bone
biopsies (19/39 patients, 48.8%) and the CT-guided biopsy samples
(16/34 patients, 47%). The rate of receptor discordance between
the primary and metastatic tumours (53.8%) was similar to that
reported in the literature [16]. The acquired tissue through bone
marrow biopsies were also of sufﬁcient quality to permit routine
molecular sequencing [20]. Given the similarity in yield of malig-
nant cells with the two procedures and that CT-guided biopsies are
considerably more expensive and resource intensive, our future
studies chose bone marrow trephine/aspiration biopsy when
studying bone metastatic bone disease [20].
Lessons learned:
1. When obtaining consent for obtaining bone biopsies it is im-
portant to consider what future studies might be performed on
these specimens so that appropriate consent can be obtained.
2. Standard operating procedures are needed for tissue handling
as different studies required different storage media (e.g. if
specimen is for IHC or genomics).
3. The clinical research associate (CRA) should be present when
biopsies are performed. Due to the many different staff mem-
bers performing the biopsies the CRA ensured that all patients
had consented, that the correct storage media was used and
that there was effective communication with the pathology
department to ensure that the appropriate tests were
performed.
2.2. Can Jamshidi bone biopsy needles be used to assess the effects of
cancer and its treatment on bone homeostasis, quality, and archi-
tecture in breast cancer patients?
Traditionally studies designed to assess bone quality in biopsystudies might be performed on these specimens.
by a well-trained individual.
s are needed for tissue handling.
latively low.
used for the assessment of bone quality, however larger studies are needed.
ndergo repeat bone biopsies.
t issue
h tumour cells present from both pre- and post-treatment specimens in the same
e teams is needed.
able however if not possible specimen storage protocols are necessary.
ilable at open surgical procedures allows for multiple end uses.
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siliac bone biopsy with a 7 mm “Bordier” core needle [21]. In this
study we examined whether or not it would be possible to use the
2 mm Jamshidi bone biopsy needle as a more practical and less
invasive method to assess bone homeostasis, quality, and archi-
tecture in humans. This feasibility study was performed on three
patients with advanced breast cancer, to evaluate metastatic spe-
cimens for bone microarchitecture, bone density, and
histomorphometry.
Trans-iliac crest bone biopsy specimens were obtained from
the posterior iliac crest using a Jamshidi bone biopsy trephine only
(i.e. no Bordier biopsy was performed), samples were then stained
and prepared for histomorphologic analysis [21]. Architectural
measurements were made using three dimensional micro-com-
puted tomography (3D microCT), while bone mineral density
(BMD) of the core biopsies were analysed using a PIXIMUS bone
densitometer. The quality of the samples obtained in this small
study was sufﬁcient for all three samples to be used for archi-
tectural measurement [21]. However, image analysis is a labour
intensive process raising concerns about the practicality of this
technique in future studies.
Lessons learned:
1. Jamshidi can be used for the assessment of bone quality. With
the increased use of adjuvant bone-targeting agents this may
offer a unique opportunity for future studies.
2. This technique may make the acquisition of bone tumour spe-
cimens more readily available for further immunohistochemical
and genetic analysis, studies in this setting are required.
2.3. Will patients agree to repeat bone biopsies?
Much more so than visceral metastases where pre and post
treatment biopsies are technically much easier to acquire, phar-
macodynamics analyses of bone-speciﬁc therapeutics represents a
unique challenge as patients may not be willing to undergo two
separate bone biopsies. Whether or not bone-speciﬁc studies can
be successfully performed on repeat bone biopsies was recently
addressed in a study conducted by our research team [22]. Fol-
lowing animal work showing that doxycycline can result in de-
crease in tumour burden in a bone metastasis model of human
breast cancer using MDA-MB-231 triple negative breast cell lines
[23], we evaluated whether or not this effect could be demon-
strated in patients with bone metastases from breast cancer [24].
In this phase II single arm, prospective study, 37 patients with
breast cancer (of any ER, PR or Her2 receptor status) and bone
metastases were enroled and received doxycycline (100 mg orally,
twice a day) in addition to their standard anticancer therapy. The
primary end point was assessment of palliative beneﬁt of adding
doxycycline for 12 weeks to standard bone-targeted therapy as
reﬂected by changes in validated pain questionnaire scores and
markers of bone turnover. In conjunction, pre- and post- 2 mm
posterior iliac crest bone biopsies were collected to evaluate the
biological effects of doxycycline on bone microenvironment. Of 37
patients, 36/37 (97%) completed a baseline biopsy. One baseline
biopsy was attempted but could not be completed for technical
reasons. While 25/37 (68%) completed the repeat week 12 bone
biopsy. Twelve patients (32%) did not complete the 12 week biopsy
because of coming off study early and they therefore did not
complete the 12 weeks of doxycycline administration (8 patients),
2 declined the repeat biopsy, and 2 biopsies were attempted but
could not be completed due to patient body habitus.
Lessons learned:
1. For intervention trials patients are often willing to undergo re-
peat biopsies however attrition during the trial intervention is asigniﬁcant issue.
2. Biopsies should be performed by a well-trained individual. If the
bone biopsy at baseline did not go smoothly the patient was
unlikely to agree to undergo a second one.
2.4. Can sufﬁcient bone metastasis cells be obtained from bone
biopsies for molecular studies?
The mechanisms of how tumour cells metastasize to bone, and
what happens to them when they get there, including their ability
to respond to treatment and treatment effects on the bone mi-
croenvironment is not fully understood in humans. For this reason
access to tumour bone metastases specimens pre and post treat-
ment interventions would be an asset. While our study success-
fully obtained paired biopsy specimens (pre and post doxycycline
treatment) for 25 patients, only 17% of baseline samples, and 12%
of week 12 bone biopsies contained metastatic tumour cells [22].
Of these, only one patient had a paired sample containing tumour
cells in both the baseline and the week 12 biopsy. Given the un-
fortunate yield of paired samples using this method, it would re-
quire signiﬁcantly larger patient cohorts to obtain sufﬁcient
numbers of paired specimens for meaningful analysis of treatment
effects directly on tumour cells. However, it should be noted that
all samples obtained had sufﬁcient bone resident cell populations,
and as such, these methods would readily allow assessment of
treatment effects on the bone microenvironment as a whole.
Lessons learned:
1. Given the relatively low yield of tumour cells in biopsies taken
from the same patient at different times alternative techniques
to increase the yield are required.
2.5. Obtaining bone biopsies at the time of orthopaedic surgery
It was evident from our previous studies that with iliac crest
biopsy there often times were no visible tumour cells in the biopsy
specimen and when they were there, their numbers were quite
low. We therefore formed an organised program for collaboration
with the local orthopaedic surgeons as most of the orthopaedic
surgery for metastatic and impending fractures in Ottawa is per-
formed at one of two hospitals. The rationale for this ongoing work
is to create cells lines in addition to creating a bone metastatic
tissue bank (bio-bank) from bone metastatic tissue from cancer
patients undergoing orthopaedic surgery. Most patients are con-
sented for this use of their tissue just prior to surgery in the
emergent situation. This consent also allows access to archival
surgical specimens of their primary tumour if it is available.
To date we have only been able to capture samples from pa-
tients who have been prescheduled for preventative orthopaedic
surgery due to risk of fracture. We have had challenges capturing
patients who are admitted for fracture through the emergency
room or trauma service, as these individuals are often admitted
and treated by a large cohort of surgeons. Additionally, we are
limited to the types of tumours place patients at a higher risk of
fracture. However from July 2014 to February 2016 we successfully
collected 29 specimens from patients undergoing orthopaedic
surgery. These specimens have come from patients with breast
cancer (n¼23), melanoma (n¼1), lung cancer (n¼1) and un-
known primary (n¼4).
Lessons learned: .
1. Successful acquisition and processing of materials required co-
ordinated efforts amongst team members from many different
departments and physical locations.
2. Wherever possible, advanced notiﬁcation allows laboratory staff
to process specimens in a timely manner. When advance
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medium for short duration at 4 °C to allow for later processing
of tumour.
3. Given the abundance of tumour available at open surgical pro-
cedures, signiﬁcant amounts of tumour and bone tissue samples
can be obtained at time of orthopaedic surgery, which allows for
multiple end uses.
4. This access to bone metastases specimens is fairly restricted to
tumour types that tend to induce risk of fracture, and as such
access to other important bone metastasizing tumours such as
prostate cancers are not readily available.3. Discussion
Despite the availability of in vivo and in vitro models for bone
metastasis behaviour there is still an ongoing need to understand
the effects of cancer and its treatment on the bone in patients.
Unfortunately obtaining human bone biopsy specimens is tech-
nically challenging and therefore our collaborative group OBOP
has performed a series of trials to try and maximise the yield of
bone metastatic tumour cells through multi-disciplinary colla-
boration. We have also attempted to prospectively ensure that
these specimens are used for future research endeavours.
In this paper, we summarized studies in which we conﬁrm the
signiﬁcant discordance in hormone receptor status between pri-
mary and metastatic bone disease at the time of metastasis [20].
We have also shown similar yields of tumour cells using the un-
guided bone marrow aspirate or the CT-guided technique, how-
ever the overall low yield of tumour cells raises questions around
the feasibility of either technique for drug evaluation studies [20].
Subsequent studies conﬁrmed that core biopsy needles could be
used to evaluate the histomorphology of the bone from metastatic
breast cancer [21]. This could prove particularly useful in future
studies evaluating the effects of various adjuvant agents on the
bone. In addition, one study conﬁrmed that patients are willing to
undergo serial bone biopsies [24]. More recently in collaboration
with our orthopaedic colleagues, we were able to obtain 29 sam-
ples to initiate the establishment of a bone tissue bank. Although
this technique is feasible, technically easy to perform and provides
adequate amounts of tissue for many studies, it is only applicable
in the subset of patients had with either acute or pending pa-
thological fracture [25],
Clearly there are limitations to our studies. They are frequently
of small size and in many of them the yield of viable tumour cells
for further studies is limited. Alternative imaging techniques have
been evaluated by others to increase the yield from bone speci-
mens [26,27]. However, these will all be limited by cost and need
of expert interventionists to perform it. Studies of circulating tu-
mour cells (CTC) and disseminated tumour cells (DTCs) are on-
going as alternatives to bone biopsy [28,29]. However, there will
still be a need for actual bone metastasis tissue as the properties of
these cells may not be the same as the cells that actually lead to
bone destruction. An interesting example is the identiﬁcation of
CTCs using Veridex as this is only tool clinically approved and is
based on Epcam expression [30]. Lobular tumours of the breast
that have a propensity for spreading to bone do not express Epcam
and therefore might not be the most effective tool for guiding
either research or patient care [31–33].4. Future directions
Through local, national and international collaborations, we
have developed a tissue acquisition program to ensure the ongoing
evaluation of bone in cancer patients. We strive to ensure thatthese valuable specimens are utilised to maximum return. Hope-
fully more centres will create similar programs to continue to
evaluate the complex interplay of bone, the tumour micro-
environment and metastatic tumour. Initial decisions about the
most appropriate site and method of bone biopsy are crucial to
enhance yield, and with improving imaging techniques, tumour
directed biopsy is likely to provide optimal tissue for real time
analysis and also tissue banking for future studies. Paired biopsies
of bone metastatic disease, other metastatic sites and potentially
circulating tumour cells may also provide further crucial in-
formation. Ultimately this collaborative work will improve the
care of not only breast cancer patients but all bone metastatic
cancer patients [11,34–36].References
[1] T. Taube, I. Elomaa, C. Blomqvist, M.N. Beneton, J.A. Kanis, Histomorphometric
evidence for osteoclast-mediated bone resorption in metastatic breast cancer,
Bone 15 (2) (1994) 161–166, PubMed PMID: 8086233.
[2] G.R. Mundy, Metastasis to bone: causes, consequences and therapeutic op-
portunities, Nat. Rev. Cancer 2 (8) (2002) 584–593, PubMed PMID: 12154351.
[3] C. Jacobs, D. Simos, C. Addison, M. Ibrahim, M. Clemons, Pharmacotherapy of
bone metastases in breast cancer patients–an update, Expert Opin. Pharmac-
other. 15 (8) (2014) 1109–1118, PubMed PMID: 24673572.
[4] R. Lahtinen, M. Laakso, I. Palva, P. Virkkunen, I. Elomaa, Randomised, placebo-
controlled multicentre trial of clodronate in multiple myeloma. Finnish leu-
kaemia group, Lancet 340 (8827) (1992) 1049–1052, PubMed PMID: 1357451.
[5] L.S. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, J. Mackey, et al., Zo-
ledronic acid versus pamidronate in the treatment of skeletal metastases in
patients with breast cancer or osteolytic lesions of multiple myeloma: a phase
III, double-blind, comparative trial, Cancer J. 7 (5) (2001) 377–387, PubMed
PMID: 11693896.
[6] N. Niikura, J. Liu, N. Hayashi, E.A. Mittendorf, Y. Gong, S.L. Palla, et al., Loss of
human epidermal growth factor receptor 2 (HER2) expression in metastatic
sites of HER2-overexpressing primary breast tumors, J. Clin. Oncol.: . J. Am.
Soc. Clin. Oncol. 30 (6) (2012) 593–599, PubMed PMID: 22124109. Pubmed
Central PMCID: 3295557.
[7] G. Aurilio, D. Disalvatore, G. Pruneri, V. Bagnardi, G. Viale, G. Curigliano, et al.,
A meta-analysis of oestrogen receptor, progesterone receptor and human
epidermal growth factor receptor 2 discordance between primary breast
cancer and metastases, Eur. J. Cancer 50 (2) (2014) 277–289, PubMed PMID:
24269135.
[8] Early Breast Cancer Trialists’ Collaborative G, R. Coleman, T. Powles,
A. Paterson, M. Gnant, S. Anderson, et al., Adjuvant bisphosphonate treatment
in early breast cancer: meta-analyses of individual patient data from rando-
mised trials, Lancet 386 (10001) (2015) 1353–1361, PubMed PMID: 26211824.
[9] T.R. Cawthorn, E. Amir, R. Broom, O. Freedman, D. Gianfelice, D. Barth, et al.,
Mechanisms and pathways of bone metastasis: challenges and pitfalls of
performing molecular research on patient samples, Clin. Exp. Metastasis 26 (8)
(2009) 935–943, PubMed PMID: 19697143.
[10] C.L. Addison, G.R. Pond, B. Cochrane, H. Zhao, S.K. Chia, M.N. Levine, et al.,
Correlation of baseline biomarkers with clinical outcomes and response to
fulvestrant with vandetanib or placebo in patients with bone predominant
metastatic breast cancer: an OCOG ZAMBONEY sub-study, J. Bone Oncol. 4 (2)
(2015) 47–53, PubMed PMID: 26579488. Pubmed Central PMCID: 4620970.
[11] X. Zhu, E. Amir, G. Singh, M. Clemons, C. Addison, Bone-targeted therapy for
metastatic breast cancer-Where do we go from here? A commentary from the
BONUS 8 meeting, J Bone Oncol. 3 (1) (2014) 1–4, PubMed PMID: 26909291.
Pubmed Central PMCID: 4723414.
[12] P.D. Ottewell, N. Wang, H.K. Brown, K.J. Reeves, C.A. Fowles, P.I. Croucher, et al.,
Zoledronic acid has differential antitumor activity in the pre- and post-
menopausal bone microenvironment in vivo, Clin. Cancer Res.: . J. Am. Assoc.
Cancer Res. 20 (11) (2014) 2922–2932, PubMed PMID: 24687923. Pubmed
Central PMCID: 4040234.
[13] R. Coleman, M. Gnant, G. Morgan, P. Clezardin, Effects of bone-targeted agents
on cancer progression and mortality, J. Natl. Cancer Inst. 104 (14) (2012)
1059–1067, PubMed PMID: 22752060.
[14] F.C. Bidard, J.Y. Pierga, J.C. Soria, J.P. Thiery, Translating metastasis-related
biomarkers to the clinic–progress and pitfalls, Nat. Rev. Clin. Oncol. 10 (3)
(2013) 169–179, PubMed PMID: 23381003.
[15] K. Russell, M. Clemons, L. Costa, C.L. Addison, Adjuvant bisphosphonate
treatment for breast cancer: Where are we heading and can the pre-clinical
literature help us get there? J. Bone Oncol. 1 (1) (2012) 12–17, PubMed PMID:
26909249. Pubmed Central PMCID: 4723323.
[16] R.J. Broom, P.A. Tang, C. Simmons, L. Bordeleau, A.M. Mulligan, F.P. O’Malley,
et al., Changes in estrogen receptor, progesterone receptor and Her-2/neu
status with time: discordance rates between primary and metastatic breast
cancer, Anticancer Res. 29 (5) (2009) 1557–1562, PubMed PMID: 19443366.
[17] E.E. Lower, E.L. Glass, D.A. Bradley, R. Blau, S. Heffelﬁnger, Impact of metastatic
M.F.K. Ibrahim et al. / Journal of Bone Oncology 5 (2016) 180–184184estrogen receptor and progesterone receptor status on survival, Breast Cancer
Res. Treat. 90 (1) (2005) 65–70, PubMed PMID: 15770528.
[18] B.G. Mobbs, E.B. Fish, K.I. Pritchard, G. Oldﬁeld, W.H. Hanna, Estrogen and
progesterone receptor content of primary and secondary breast carcinoma:
inﬂuence of time and treatment, Eur. J. Cancer Clin. Oncol. 23 (6) (1987)
819–826, PubMed PMID: 3653198.
[19] E. Amir, N. Miller, W. Geddie, O. Freedman, F. Kassam, C. Simmons, et al.,
Prospective study evaluating the impact of tissue conﬁrmation of metastatic
disease in patients with breast cancer, J. Clin. Oncol.: . J. Am. Soc. Clin. Oncol.
30 (6) (2012) 587–592, PubMed PMID: 22124102.
[20] J.F. Hilton, E. Amir, S. Hopkins, M. Nabavi, G. DiPrimio, A. Sheikh, et al., Ac-
quisition of metastatic tissue from patients with bone metastases from breast
cancer, Breast Cancer Res. Treat. 129 (3) (2011) 761–765, PubMed PMID:
21113656.
[21] M. Fralick, N. Bouganim, R. Kremer, N. Kekre, S. Robertson, L. Vandermeer,
et al., Histomorphometric and microarchitectural analyses using the 2mm
bone marrow trephine in metastatic breast cancer patients - preliminary re-
sults, J. Bone Oncol. 1 (3) (2012) 69–73.
[22] NCT01847976, A Phase 2 Trial Exploring the Clinical and Correlative Effects of
Combining Doxycycline With Bone-Targeted Therapy in Patients With Meta-
static Breast Cancer, Available from: 〈https://clinicaltrials.gov/ct2/show/
NCT01847976〉.
[23] W.C. Duivenvoorden, S. Vukmirovic-Popovic, M. Kalina, E. Seidlitz, G. Singh,
Effect of zoledronic acid on the doxycycline-induced decrease in tumour
burden in a bone metastasis model of human breast cancer, Br. J. Cancer 96
(10) (2007) 1526–1531, PubMed PMID: 17437017. Pubmed Central PMCID:
2359943.
[24] clinicalTrials.gov. Combining Doxycycline With Bone-Targeted Therapy in Pa-
tients With Metastatic Breast Cancer (OTT12-05) NCT01847976 2016 [cited
2016 February 25]. Available from: 〈https://clinicaltrials.gov/ct2/show/
NCT01847976〉.
[25] F. Saad, A. Lipton, R. Cook, Y.M. Chen, M. Smith, R. Coleman, Pathologic frac-
tures correlate with reduced survival in patients with malignant bone disease,
Cancer 110 (8) (2007) 1860–1867, PubMed PMID: 17763372.
[26] R. Blanco Sequeiros, R. Klemola, R. Ojala, L. Jyrkinen, E. Lappi-Blanco, Y. Soini,
et al., MRI-guided trephine biopsy and ﬁne-needle aspiration in the diagnosisof bone lesions in low-ﬁeld (0.23 T) MRI system using optical instrument
tracking, Eur. Radiol. 12 (4) (2002) 830–835, PubMed PMID: 11960234.
[27] R.K. Parkkola, K.T. Mattila, J.T. Heikkila, T.O. Ekfors, M.A. Kallajoki, M.E. Komu,
et al., Dynamic contrast-enhanced MR imaging and MR-guided bone biopsy
on a 0.23 T open imager, Skelet. Radiol. 30 (11) (2001) 620–624, PubMed
PMID: 11810153.
[28] J.W. Uhr, K. Pantel, Controversies in clinical cancer dormancy, Proc. Natl. Acad.
Sci. USA 108 (30) (2011) 12396–12400, PubMed PMID: 21746894. Pubmed
Central PMCID: 3145712.
[29] K. Pantel, C. Alix-Panabieres, S. Riethdorf, Cancer micrometastases, Nat. Rev.
Clin. Oncol. 6 (6) (2009) 339–351, PubMed PMID: 19399023.
[30] C. Alix-Panabieres, H. Schwarzenbach, K. Pantel, Circulating tumor cells and
circulating tumor DNA, Annu. Rev. Med. 63 (2012) 199–215, PubMed PMID:
22053740.
[31] C. Jacobs, M. Clemons, C. Addison, S. Robertson, A. Arnaout, Issues affecting the
loco-regional and systemic management of patients with invasive lobular
carcinoma of the breast, Breast J. 22 (1) (2016) 45–53, PubMed PMID:
26782951.
[32] K. Al-Baimani, A. Bazzarelli, M. Clemons, S.J. Robertson, C. Addison, A. Arnaout,
Invasive pleomorphic lobular carcinoma of the breast: pathologic, clinical, and
therapeutic considerations, Clin. Breast Cancer 15 (6) (2015) 421–425, PubMed
PMID: 26209026.
[33] C. Jacobs, M.F. Ibrahim, M. Clemons, B. Hutton, D. Simos, J.M. Caudrelier, et al.,
Treatment choices for patients with invasive lobular breast cancer: a doctor
survey, J. Eval. Clin. Pract. 21 (4) (2015) 740–748, PubMed PMID: 26059404.
[34] I. Kuchuk, D. Simos, C.L. Addison, M. Clemons, A national portfolio of bone
oncology trials-The Canadian experience in 2012, J. Bone Oncol. 1 (3) (2012)
95–100, PubMed PMID: 26909263. Pubmed Central PMCID: 4723348.
[35] V. Ouellet, K. Tiedemann, A. Mourskaia, J.E. Fong, D. Tran-Thanh, E. Amir, et al.,
CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor
breast cancer metastasis to bone, Am. J. Pathol. 178 (5) (2011) 2377–2388,
PubMed PMID: 21514448. Pubmed Central PMCID: 3081179.
[36] M. Trinkaus, W.S. Ooi, E. Amir, S. Popovic, M. Kalina, H. Kahn, et al., Ex-
amination of the mechanisms of osteolysis in patients with metastatic breast
cancer, Oncol. Rep. 21 (5) (2009) 1153–1159, PubMed PMID: 19360288.
